64 related articles for article (PubMed ID: 1731053)
21. Disposition of antineoplastic agents in the very young child.
McLeod HL; Relling MV; Crom WR; Silverstein K; Groom S; Rodman JH; Rivera GK; Crist WM; Evans WE
Br J Cancer Suppl; 1992 Aug; 18():S23-9. PubMed ID: 1503923
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.
Petros WP; Rodman JH; Mirro J; Evans WE
Cancer Chemother Pharmacol; 1991; 27(5):397-400. PubMed ID: 1999001
[TBL] [Abstract][Full Text] [Related]
23. Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.
McLeod HL; Baker DK; Pui CH; Rodman JH
Cancer Chemother Pharmacol; 1991; 29(2):150-4. PubMed ID: 1760858
[TBL] [Abstract][Full Text] [Related]
24. Clinical trials of teniposide (VM-26) in childhood acute lymphocytic leukemia.
Rivera GK; Evans WE
Semin Oncol; 1992 Apr; 19(2 Suppl 6):51-8. PubMed ID: 1411639
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress and total antioxidant status in acute leukemia at diagnosis and post remission induction phase.
Naz A; Shamsi TS; Sattar A; Mahboob T
Pak J Pharm Sci; 2013 Nov; 26(6):1123-30. PubMed ID: 24191316
[TBL] [Abstract][Full Text] [Related]
27. [Allergic reactions to teniposide (VM-26) in children with neoplasms].
Wysocki M; Nowaczyk-Michalak A; Pilecki O
Wiad Lek; 1992 Feb; 45(3-4):91-3. PubMed ID: 1413803
[TBL] [Abstract][Full Text] [Related]
28. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
J Clin Oncol; 1990 Nov; 8(11):1874-9. PubMed ID: 2230875
[TBL] [Abstract][Full Text] [Related]
29. Teniposide for acute lymphoblastic leukemia.
Med Lett Drugs Ther; 1992 Nov; 34(883):105-6. PubMed ID: 1435505
[No Abstract] [Full Text] [Related]
30. Low levels of serum transport proteins indicate catabolic protein status during induction therapy for acute lymphoblastic leukemia.
Koskelo EK; Saarinen UM; Siimes MA
Pediatr Hematol Oncol; 1991; 8(1):53-9. PubMed ID: 1903045
[TBL] [Abstract][Full Text] [Related]
31. Age-related differences in hepatic drug clearance in children: studies with lorazepam and antipyrine.
Crom WR; Relling MV; Christensen ML; Rivera GK; Evans WE
Clin Pharmacol Ther; 1991 Aug; 50(2):132-40. PubMed ID: 1868674
[TBL] [Abstract][Full Text] [Related]
32. Effect of cyclosporin A on protein binding of teniposide in cancer patients.
Toffoli G; Aita P; Sorio R; Corona G; Bertola A; Colussi AM; Robieux I; Boiocchi M
Anticancer Drugs; 1999 Jul; 10(6):511-8. PubMed ID: 10885897
[TBL] [Abstract][Full Text] [Related]
33. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy.
Relling MV; Crom WR; Pieper JA; Cupit GC; Rivera GK; Evans WE
Clin Pharmacol Ther; 1987 Jun; 41(6):651-60. PubMed ID: 3472701
[TBL] [Abstract][Full Text] [Related]
34. Hepatic drug clearance in children: studies with indocyanine green as a model substrate.
Evans WE; Relling MV; de Graaf S; Rodman JH; Pieper JA; Christensen ML; Crom WR
J Pharm Sci; 1989 Jun; 78(6):452-6. PubMed ID: 2760818
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia.
Crom WR; de Graaf SS; Synold T; Uges DR; Bloemhof H; Rivera G; Christensen ML; Mahmoud H; Evans WE
J Pediatr; 1994 Oct; 125(4):642-9. PubMed ID: 7931891
[TBL] [Abstract][Full Text] [Related]
36. Effect of induced hypoalbuminemia on distribution, total clearance and unbound clearance of piroxicam in vivo in the rat.
Troconiz JI; Lopez-Bustamante LG; Fos D
Eur J Drug Metab Pharmacokinet; 1993; 18(2):165-71. PubMed ID: 8243500
[TBL] [Abstract][Full Text] [Related]
37. Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer.
Gigante M; Sorio R; Colussi AM; Sandrin A; De Appollonia L; Galligioni E; Freschi A; Talamini R; Toffoli G; Boiocchi M
Anticancer Drugs; 1995 Jun; 6(3):479-82. PubMed ID: 7670149
[TBL] [Abstract][Full Text] [Related]
38. Targeting the systemic exposure of teniposide in the population and the individual using a stochastic therapeutic objective.
D'Argenio DZ; Rodman JH
J Pharmacokinet Biopharm; 1993 Apr; 21(2):223-51. PubMed ID: 8229682
[TBL] [Abstract][Full Text] [Related]
39. On the oncology front.
Meyer C
Am J Nurs; 1993 Mar; 93(3):63-4. PubMed ID: 8095122
[No Abstract] [Full Text] [Related]
40. Anticancer therapy as a pediatric pharmacodynamic paradigm.
Evans WE; Relling MV; Rodman JH; Crom WR
Dev Pharmacol Ther; 1989; 13(2-4):85-95. PubMed ID: 2693007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
